a. Discussion of confidential intellectual property or work product and prepublication, confidential scientific
research or data relating to Major Facilities applications. (Health & Safety Code 125290.30(d) (3) (B) and
b. Discussion of Personnel (Government Code section 11126, subdivision (a); Health & Safety Code section
125290.30(d) (3) (D)).
c. Pending Litigation (Government Code section 11126, subdivision (e)): Mary Scott Doe v. Robert Klein, et al.
Public report of any action taken, if necessary, during closed session.
Consideration of definition of “California Supplier.”
Consideration of equipment funding for Major Facilities program.
Consideration of recommendations from ICOC subcommittee regarding definitions and requirements for CIRM RFAs including, but not limited to, definition of PI, minimum required effort by PIs and number of application submissions per institution.
Public comment. The Committee will accept public testimony on any matter under its jurisdiction that is not on the agenda, but the Committee cannot act on any such matter at this meeting.
THE ORDER OF BUSINESS MAY BE CHANGED WITHOUT NOTICE.
Notice is hereby given that the order of consideration of matters on this agenda may be changed without prior notice.
The California Institute for Regenerative Medicine and its Independent Citizens Oversight Committee, and any subcommittees thereof, comply with the Americans with Disabilities Act (ADA) by ensuring that the meeting facilities are accessible to persons with disabilities, and providing that this notice and information given to the Members of the Committee is available to the public in appropriate alternative formats when requested. If you need further assistance, including disability-related modifications or accommodations, you may contact Melissa King at the California Institute for Regenerative Medicine at 415-396-9100 no later than the day prior to the meeting.
Questions or requests for additional information prior to the Independent Citizens Oversight Committee meeting may be referred to Melissa King at the California Institute for Regenerative Medicine at firstname.lastname@example.org or 415-396-9100.
This meeting agenda is also available on the website for the California Institute for Regenerative Medicine at https://www.cirm.ca.gov.